A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced that Phase 1b data for IBC-Ab002, a newly engineered ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

LAG-3 and TIGIT expression may predict skin melanoma progression and survival. Discover how these immune markers could shape future therapies. Read more.

Virus-associated cancers are a significant and persistent global health challenge, providing unique insight into the relationship between chronic infection ...